Program in Clinical and Translational Neuromuscular Research
We are also planning investigation of the hereditary neuropathies (i.e., Charcot Marie Tooth disease). Our program is a part of the Muscle Study Group (MSG), which is a consortium of scientific investigators among academic and research centers committed to the cooperative planning, implementation, analysis and reporting of controlled clinical trials and of other research for muscle and other neuromuscular diseases.
- Richard J. Nowak, MD, MS, Director
- Joan Nye, BS, Clinical Research Coordinator
Faculty, Collaborators and Staff
- Kevin C. O’Connor, PhD, Assistant Professor of Neurology
- Jonathan M. Goldstein, MD, Associate Professor of Neurology
- Daniel B. DiCapua, MD, Assistant Professor of Neurology
- Benison Keung, MD, Instructor in Neurology
- Pam Clark, BS
Immunologic Markers of Myasthenia Gravis
The purpose of the exploratory research study is to collect blood samples from people with MG. Through analysis of these specimens, the researcher hope to learn more about the underlying pathophysiology of MG, as well as find unique biological markers, which could be used to develop new therapies.
Efficacy of Prednisone in the Treatment of Ocular Myasthenia: The EPITOME Study
The purpose of this study is to determine if prednisone is an effective therapy for newly diagnosed ocular myasthenia gravis (OMG) patients, in addition to pyridostigmine. This is a randomized, double-blind, placebo controlled study. (Recruitment Letter)
Immunologic Biomarkers in the Efficacy of Prednisone in the Treatment of Ocular Myasthenia: The IB-EPITOME Study
This is an ancillary biomarker study for the EPITOME study. Subjects participating in the EPITOME study can also enroll in IB-EPITOME. The purpose of this study is to explore how treatment modifies the immunopathology of ocular myasthenia gravis and to identify markers of disease activity.
The International Guillain-Barré syndrome Outcome Study (IGOS)
IGOS is a worldwide prospective study, conducted by the Inflammatory Neuropathy Consortium (INC), that aims to define biomarkers for disease activity and recovery and to develop prognostic models to predict the clinical course and outcome in individual patients with Guillain-Barré syndrome (GBS). The study will enroll 1000 subjects from over 100 centers.
For any questions regarding our program, interest in participating in one of our trials or collaboration opportunities please contact the program director, Dr. Richard Nowak (email@example.com) or the clinical research coordinator, Joan Nye (firstname.lastname@example.org). To support our ongoing efforts please join our team and make a gift toward neuromuscular research contact Sharon McManus (email@example.com).